{"gene":"NGLY1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2000,"finding":"PNG1 (yeast ortholog of NGLY1) encodes a soluble cytosolic/nuclear peptide:N-glycanase; when expressed in E. coli it exhibits PNGase enzymatic activity, cleaving N-glycans from glycoproteins/glycopeptides. Subcellular fractionation showed Png1p is present in both nucleus and cytosol. Loss of png1 function reduces efficiency of proteasome-mediated degradation of a misfolded glycoprotein.","method":"Genetic screen for PNGase-deficient mutants, recombinant expression in E. coli with enzymatic activity assay, subcellular fractionation/localization","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution in E. coli, genetic loss-of-function with defined degradation phenotype, subcellular fractionation; foundational paper replicated across multiple subsequent studies","pmids":["10831608"],"is_preprint":false},{"year":2001,"finding":"Yeast Png1p (NGLY1 ortholog) physically interacts with Rad23p, a ubiquitin-binding protein that links substrates to the 26S proteasome. The Png1p-Rad23p complex is distinct from the Rad4p-Rad23p DNA repair complex. Rad23p is proposed to act as an escort linking Png1p (and thus deglycosylated substrates) to the 26S proteasome.","method":"Two-hybrid screening, co-immunoprecipitation (in vivo biochemical confirmation)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — interaction identified by yeast two-hybrid and confirmed by reciprocal biochemical co-IP; replicated and extended in subsequent studies","pmids":["11259433"],"is_preprint":false},{"year":2006,"finding":"The Png1-Rad23 complex in yeast is required for efficient degradation of a glycosylated ERAD substrate (glycosylated ricin A chain), coupling protein deglycosylation to proteasomal degradation. Rad23 binds various regulators of proteolysis to facilitate degradation of distinct substrates, with substrate specificity determined by interactions with cofactors.","method":"Genetic deletion of PNG1/RAD23, glycoprotein turnover assay (glycosylated ricin A chain degradation), protein interaction studies","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function with defined substrate degradation readout, functional complex characterized, replicated across labs","pmids":["16401726"],"is_preprint":false},{"year":2009,"finding":"The Neurospora crassa PNG1 ortholog has substitutions in essential catalytic amino acids, abolishing deglycosylation activity, yet PNG1 is essential for cell polarity; its deletion causes strong polarity defects. This reveals an enzyme-independent (non-catalytic) scaffolding function of PNG1 in polar cell growth, distinct from its role in ERAD.","method":"Gene deletion, catalytic mutant analysis, morphological phenotyping in Neurospora crassa","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with defined polarity phenotype and catalytic mutant showing enzyme-independent function; single organism, single lab","pmids":["19940117"],"is_preprint":false},{"year":2010,"finding":"Loss-of-function mutations in C. elegans png-1 (NGLY1 ortholog) cause increased axon branching during morphogenesis of vulval egg-laying neurons (VC4, VC5) and nearby axons. PNG-1 acts from both neurons and epithelial cells to restrict axon branching. Genetic interaction with rad-23 (Rad23 ortholog) shows similar branching defects, placing png-1 and rad-23 in the same pathway regulating neuronal branching during organ innervation.","method":"Loss-of-function genetic screen in C. elegans, neuronal morphology analysis, tissue-specific rescue, genetic epistasis with rad-23","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function with defined neuronal phenotype, tissue-specific rescue, genetic epistasis; multiple orthogonal approaches in single rigorous study","pmids":["20130186"],"is_preprint":false},{"year":2015,"finding":"In Ngly1-/- mouse embryonic fibroblasts (MEFs), loss of Ngly1 causes delayed degradation of misfolded ERAD substrates. In the absence of Ngly1, ENGase (endo-β-N-acetylglucosaminidase) performs an alternative deglycosylation reaction generating N-GlcNAc proteins that are aggregation-prone. Additional knockout of ENGase in Ngly1-/- cells restores normal ERAD processing, demonstrating that ENGase-generated N-GlcNAc protein aggregates underlie ERAD dysregulation in NGLY1 deficiency.","method":"MEF knockout cell lines (Ngly1-/- and Ngly1-/-/ENGase-/-), glycoprotein degradation assays, protein aggregation analysis, genetic epistasis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — double knockout genetic epistasis with defined ERAD substrate degradation and aggregation readouts; multiple orthogonal methods in single study","pmids":["25605922"],"is_preprint":false},{"year":2017,"finding":"NGLY1 (human cytosolic N-glycanase) is essential for activation of the transcription factor NFE2L1 (Nrf1) in response to proteasome inhibition. NGLY1 processes retrotranslocated, N-glycosylated Nrf1 by removing its N-glycans; chemical or genetic disruption of NGLY1 results in misprocessed Nrf1 that is excluded from the nucleus and cannot upregulate proteasome subunit gene expression (the 'bounce-back' response). A small-molecule NGLY1 inhibitor was identified that disrupts Nrf1 processing and potentiates proteasome inhibitor cytotoxicity.","method":"Genetic KO, siRNA knockdown, small-molecule NGLY1 inhibitor, reporter assays for Nrf1 nuclear localization and transcriptional activity, cell viability assays","journal":"ACS central science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic KO, RNAi, chemical inhibitor) with defined mechanistic readout (Nrf1 processing, nuclear localization, transcriptional activity); replicated across cell lines","pmids":["29202016"],"is_preprint":false},{"year":2017,"finding":"Lethality of Ngly1-/- mice (C57BL/6 background) is partially rescued by additional deletion of the ENGase gene, establishing a genetic epistasis relationship. This demonstrates that ENGase-generated N-GlcNAc protein aggregates are a primary pathological driver in NGLY1 deficiency, and identifies cytoplasmic ENGase as a potential therapeutic target.","method":"Double knockout mouse genetics (Ngly1-/- x ENGase-/-), survival analysis, phenotypic rescue","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with survival endpoint; confirms prior MEF cell data at organismal level","pmids":["28426790"],"is_preprint":false},{"year":2018,"finding":"NGLY1 regulates mitochondrial homeostasis through the transcription factor NRF1 (NFE2L1). NGLY1-deficient human and mouse cells show impaired mitochondrial clearance by mitophagy, resulting in fragmented mitochondria and chronic activation of cytosolic nucleic acid-sensing pathways (cGAS-STING and MDA5-MAVS), leading to elevated interferon gene signature. Pharmacological activation of NRF2, a non-glycosylated homolog of NRF1, restores mitochondrial homeostasis and suppresses immune gene activation in NGLY1-deficient cells.","method":"NGLY1-deficient human and mouse cell lines, mitophagy assays, mitochondrial morphology/function assays, cGAS-STING/MDA5-MAVS pathway activation measurements, NRF2 activator rescue experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (mitophagy assay, pathway activation, pharmacological rescue) across human and mouse cells with mechanistic pathway placement","pmids":["30135079"],"is_preprint":false},{"year":2018,"finding":"In a Drosophila model of NGLY1 deficiency (loss of Pngl), transcriptome analysis shows no evidence of ER stress but reveals strong NRF1 dysfunction signature (downregulation of proteasome components and oxidation-reduction genes). Loss of NGLY1 is functionally linked to defects in neuroendocrine signaling; targeted NGLY1 expression in prothoracic gland (ecdysteroid-producing tissue) or supplementation with the molting hormone 20-hydroxyecdysone partially rescues developmental delay.","method":"Drosophila Pngl loss-of-function model, RNAseq transcriptome analysis, tissue-specific rescue (Gal4/UAS), pharmacological rescue (20-hydroxyecdysone)","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics plus genetic/pharmacological rescue in Drosophila; mechanistic pathway placement through NRF1 signature and neuroendocrine axis","pmids":["29346549","29735526"],"is_preprint":false},{"year":2020,"finding":"Loss of NGLY1 in Drosophila visceral muscle leads to severely reduced AMPKα (AMP-activated protein kinase α) levels, causing energy metabolism defects, impaired gut peristalsis, and animal lethality. Reduced AMPKα levels are also observed in Ngly1-/- mouse embryonic fibroblasts and NGLY1-deficient patient fibroblasts. Pharmacological AMPK activation suppresses energy metabolism defects. This AMPKα reduction is not caused by loss of NFE2L1 activity, defining an NRF1-independent NGLY1 pathway.","method":"Drosophila tissue-specific genetics, Ngly1-/- MEFs, patient fibroblasts, AMPKα western blot, pharmacological AMPK activation, epistasis with NFE2L1","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — conserved finding across three species/models (fly, mouse, human patient cells), multiple orthogonal methods, epistasis establishing NRF1-independence","pmids":["33315951"],"is_preprint":false},{"year":2020,"finding":"Loss of NGLY1 in a Drosophila genetic diversity panel reveals NKCC1/2 (ion cotransporter; Drosophila Ncc69) as a modifier of NGLY1 deficiency lethality. In NGLY1-/- mouse cells, NKCC1 shows altered average molecular weight and reduced function, suggesting NKCC1 is a relevant NGLY1 substrate or functionally dependent on NGLY1 activity.","method":"Drosophila NGLY1 deficiency model crossed to genetically diverse strains, association analysis, evolutionary rate covariation, NGLY1-/- mouse cell NKCC1 functional assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic screen plus functional validation in mouse cells across two model systems; NKCC1 mechanism not fully resolved at molecular level","pmids":["33315011"],"is_preprint":false},{"year":2014,"finding":"Yeast Png1p deglycosylates ricin A chain (RTA) in the cytosol, and this deglycosylation increases RTA depurination activity by apparently protecting it from ERAD-mediated degradation. In contrast, for a less toxic G83D variant, Png1p deglycosylation on the ER membrane promotes its degradation and reduces toxicity, demonstrating that the free cytosolic pool vs. ER-membrane-associated Png1 have distinct substrate preferences and opposing functional consequences.","method":"Yeast genetic deletion of PNG1, EGFP-tagged RTA trafficking assays, depurination activity assays, toxicity assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic loss-of-function with defined enzymatic and toxicity readouts; single lab, multiple substrates tested","pmids":["25436896"],"is_preprint":false},{"year":2019,"finding":"Loss of Ngly1 in hepatocyte-specific conditional knockout mice causes impaired processing and nuclear localization of Nfe2l1 (NRF1) in hepatocytes, contributing to abnormal hepatocyte nuclear morphology and lipid accumulation under high-fructose diet stress. This establishes that NGLY1 is required for proper Nfe2l1 processing and function in liver tissue in vivo.","method":"Liver-specific Cre-loxP conditional Ngly1 knockout mice, Nfe2l1 processing/localization assays, liver phenotype analysis under dietary stress","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific in vivo KO with defined molecular (Nfe2l1 processing) and phenotypic (nuclear morphology, lipid) readouts; single lab","pmids":["31733337"],"is_preprint":false},{"year":2022,"finding":"NFE2L1/NRF1 promotes ferroptosis resistance through maintaining expression of glutathione peroxidase 4 (GPX4), and this function requires NGLY1-dependent processing of NFE2L1. NGLY1-mediated NFE2L1 activation is independent of NFE2L2/NRF2, establishing that the NGLY1-NFE2L1 axis constitutes a distinct pathway regulating ferroptosis.","method":"NGLY1/NFE2L1 genetic KO cell lines, ferroptosis assays, GPX4 expression analysis, epistasis between NFE2L1 and NFE2L2","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined ferroptosis/GPX4 readout and epistasis; single lab, multiple cell lines","pmids":["35271393"],"is_preprint":false},{"year":2022,"finding":"In C. elegans, PNG-1/NGLY1 deglycosylates the transcription factor SKN-1A/Nrf1 by converting N-glycosylated asparagine residues to aspartate ('sequence editing'), and this chemical conversion is strictly required for SKN-1A transcriptional activation of proteasome subunit genes. Sequence-edited SKN-1A can also activate redox homeostasis and xenobiotic detoxification genes normally regulated by SKN-1C/Nrf2, but sequence editing itself antagonizes the extent of this activation.","method":"C. elegans genetics, transcriptomic analysis, mutant alleles selectively inactivating SKN-1A or SKN-1C, deglycosylation/sequence editing assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic approach with transcriptomic readout, multiple selective mutant alleles; preprint, not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2022,"finding":"NGLY1 inhibition (pharmacological via Z-VAD-fmk, or siRNA knockdown) induces upregulation of autophagosome formation without impairing autophagic flux in HEK293 cells. This autophagy induction does not involve ER stress markers, ROS, or altered Ca2+ handling. ATG13-deficient MEFs show reduced viability under NGLY1 inhibition, establishing that autophagy is a cytoprotective adaptation to NGLY1 loss.","method":"Pharmacological NGLY1 inhibition (Z-VAD-fmk), siRNA knockdown, GFP-LC3 puncta assay, autophagosome immunoprecipitation with mass spectrometry, ATG13-KO MEFs","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods of NGLY1 inhibition with autophagy readout, genetic validation with ATG13 KO; single lab","pmids":["34995415"],"is_preprint":false},{"year":2024,"finding":"NGLY1 physically interacts with and deglycosylates cancer cell-intrinsic PD-1 in response to doxorubicin treatment. Doxorubicin promotes the interaction between NGLY1 and PD-1, facilitating NGLY1-mediated PD-1 deglycosylation and destabilization (shortening PD-1 half-life), thereby sensitizing tumor cells to doxorubicin's antiproliferative effects.","method":"Co-immunoprecipitation (NGLY1-PD-1 interaction), protein half-life assay, siRNA knockdown of NGLY1, doxorubicin treatment, cell viability assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating interaction, protein stability assay, and functional cell viability readout; single lab, single paper","pmids":["38782868"],"is_preprint":false},{"year":2024,"finding":"Crystal structure of bovine FBS2 (component of SCF-FBS2 ubiquitin ligase) complexed with SKP1 and the N-glycan core pentasaccharide Man3GlcNAc2 was determined, revealing the structural basis for sugar recognition. NMR data revealed disparate sugar-binding specificities among homologous FBS proteins and identified a druggable pocket. FBS2 recognizes N-glycan remnants on proteins processed in the NGLY1/ERAD pathway.","method":"X-ray crystallography, NMR spectroscopy, in silico docking","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus NMR validation; single lab but two orthogonal structural methods","pmids":["39171510"],"is_preprint":false},{"year":2024,"finding":"NGLY1 possesses a 'sequence editing' enzymatic function: it converts N-glycosylated asparagine residues to aspartate residues on substrate proteins (not merely removing glycans), introducing negative charges into the core peptide. An ELISA-based assay using this Asn-to-Asp conversion to generate a neo-epitope confirmed endogenous NGLY1 activity detectable in as few as 5×10³ cells, including patient-derived iPSCs.","method":"ELISA-based activity assay exploiting Asn-to-Asp conversion (neo-epitope detection by anti-HA antibody), crude cell extract from patient and control iPSCs","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with defined chemical conversion readout; functional validation in patient-derived cells; single lab","pmids":["38581946"],"is_preprint":false},{"year":2024,"finding":"A FRET-based probe assay revealed significant changes in NGLY1 enzymatic activity in rat brains during aging, demonstrating that endogenous NGLY1 activity is dynamically regulated in the central nervous system under physiological conditions.","method":"FRET-based fluorescent glycopeptide probe, plate-based assay of endogenous NGLY1 activity in rat brain tissues across ages","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — quantitative in vitro enzymatic assay of endogenous enzyme; novel finding about age-dependent regulation; single lab","pmids":["38417795"],"is_preprint":false},{"year":2025,"finding":"The STING pathway drives noninflammatory neurodegeneration in NGLY1 deficiency. In postnatal inducible whole-body Ngly1 knockout mice, genetic ablation of Sting1 rescues Purkinje cell loss, improves motor function, and extends lifespan without requiring immune/inflammatory activation. Single-nucleus RNA sequencing reveals STING-dependent suppression of cholesterol biosynthesis in glia. Pharmacological STING inhibition with VS-X4 mitigates neuropathology and motor disease.","method":"Postnatal inducible Ngly1 KO mouse, genetic Sting1 ablation (double KO), single-nucleus RNA sequencing, pharmacological STING inhibition (VS-X4), motor function assays, histopathology","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis (double KO rescue), snRNA-seq pathway analysis, pharmacological confirmation with defined neuropathological and behavioral endpoints","pmids":["40644312"],"is_preprint":false},{"year":2023,"finding":"Loss of Drosophila N-glycanase 1 (Pngl) in a specific intestinal cell type causes gut barrier defects leading to starvation and JNK overactivation; combined loss in enterocytes and fat body causes Foxo overactivation, hyperactive innate immune response, and enhanced lipid catabolism contributing to lethality. Germ-free rearing rescues developmental delay but not lethality, indicating lethality is primarily driven by non-bacterial immune/metabolic mechanisms rather than microbiota.","method":"Tissue-specific Drosophila Pngl knockouts, germ-free rearing, fat-rich diet rescue, JNK/Foxo pathway analysis, intestinal barrier assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific in vivo genetics, multiple epistasis experiments, germ-free and dietary rescue with defined pathway (JNK/Foxo) readouts","pmids":["37704604"],"is_preprint":false},{"year":2023,"finding":"NGLY1 deficiency in human iPSC-derived cortical neurons (but not astrocytes) causes protein aggregate accumulation, mitochondrial homeostasis defects, and synaptic dysfunction. Laser capture microscopy and mass spectrometry characterized the composition of protein aggregates specific to NGLY1-deficient neurons. Introduction of functional NGLY1 rescued these phenotypes, confirming direct causality.","method":"iPSC direct conversion to cortical neurons, transcriptomics, proteomics, functional assays, NGLY1 rescue, laser capture microscopy and mass spectrometry of aggregates","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — patient iPSC-derived neurons with multiple orthogonal methods (transcriptomics, proteomics, functional assays) and genetic rescue; cell-type specificity established","pmids":["38039131"],"is_preprint":false},{"year":2024,"finding":"Mutations in nucleotide metabolism genes (rsks-1, tald-1, ent-4) suppress proteasome inhibitor sensitivity caused by PNG-1/NGLY1 inactivation in C. elegans through an SKN-1/Nrf1-independent mechanism. Restriction of nucleotide availability (via ent-4 intestinal nucleoside/nucleotide transporter mutation or dietary manipulation) is beneficial, while a nucleotide-rich diet exacerbates proteasome dysfunction in PNG-1/NGLY1-deficient worms.","method":"C. elegans suppressor screen, double mutant epistasis, dietary nucleotide manipulation, proteasome function assays","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic suppressor screen with epistasis; novel NRF1-independent pathway; single organism/lab","pmids":["38991033"],"is_preprint":false},{"year":2025,"finding":"Natural variants in SEL1L (cytoplasmic tail domain, S780P and Δ806-809) modify NGLY1 deficiency lethality in Drosophila by enhancing ERAD function in an NGLY1-dependent manner. This genetic interaction implicates NGLY1 as a contributor to general ERAD function (not solely deglycosylation of specific substrates), and SEL1L variants also protect against proteasome inhibition sensitivity in heterozygous NGLY1 null flies.","method":"CRISPR-generated Drosophila SEL1L variant lines, NGLY1 deficiency model genetic interaction, ERAD functional assays, ER stress resistance assays, proteasome inhibition assays","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR-engineered variants with ERAD functional readouts and genetic interaction with NGLY1; single lab, Drosophila model","pmids":["40773511"],"is_preprint":false},{"year":2025,"finding":"NGLY1 exhibits a novel exo-(N-)glycanase activity on ENGase-digested N-GlcNAc proteins in vitro, distinct from its canonical endo-(N-)glycanase activity. Active sites for exo-NGLY1 activity were predicted computationally and differ from those of endo-NGLY1.","method":"In vitro enzymatic assay with N-GlcNAc protein substrates, computational active-site prediction/comparison","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — novel in vitro activity described in preprint; single lab, no mutagenesis or structural validation of predicted exo-active site","pmids":[],"is_preprint":true}],"current_model":"NGLY1 is a cytosolic amidase (peptide:N-glycanase) that removes N-linked glycans from misfolded glycoproteins retrotranslocated from the ER, converting N-glycosylated asparagine residues to aspartate ('sequence editing'); it forms a complex with RAD23 to couple deglycosylation to proteasomal degradation, is essential for NFE2L1/NRF1 transcription factor activation (which requires NGLY1-mediated deglycosylation for nuclear translocation and proteasome bounce-back gene expression), regulates mitochondrial homeostasis and mitophagy through NRF1, controls AMPK signaling and energy metabolism, and activates the STING innate immune pathway under conditions of proteostatic stress; in its absence, the alternative deglycosylase ENGase generates aggregation-prone N-GlcNAc proteins that are the primary pathological drivers of NGLY1 deficiency."},"narrative":{"mechanistic_narrative":"NGLY1 is a soluble cytosolic/nuclear peptide:N-glycanase that drives the cytoplasmic deglycosylation arm of ER-associated degradation (ERAD), removing N-linked glycans from misfolded glycoproteins retrotranslocated from the ER and coupling their turnover to the proteasome [PMID:10831608, PMID:16401726]. Rather than simply excising sugars, the enzyme performs 'sequence editing', deamidating the glycosylated asparagine to aspartate and thereby introducing a permanent negative charge into the substrate peptide [PMID:38581946]. It is escorted to the 26S proteasome through a direct physical interaction with the ubiquitin-binding protein RAD23, which links deglycosylated substrates to degradation [PMID:11259433, PMID:16401726]. A central physiological output of this activity is activation of the transcription factor NFE2L1/NRF1: NGLY1-mediated processing of retrotranslocated NRF1 is strictly required for its nuclear entry and induction of the proteasome 'bounce-back' response [PMID:29202016], and this axis extends to mitochondrial homeostasis and mitophagy, ferroptosis resistance via GPX4, and in vivo hepatic NRF1 function [PMID:30135079, PMID:35271393, PMID:31733337]. NGLY1 also acts through NRF1-independent routes, maintaining AMPKα levels and energy metabolism across fly, mouse, and patient cells [PMID:33315951]. In NGLY1 deficiency the alternative deglycosidase ENGase generates aggregation-prone N-GlcNAc proteins that are the primary pathological drivers, since deleting ENGase restores ERAD and partially rescues lethality [PMID:25605922, PMID:28426790]. Loss of NGLY1 produces neuronal protein aggregation, mitochondrial and synaptic defects in human iPSC-derived cortical neurons [PMID:38039131], and STING-dependent neurodegeneration in mice that is rescued by Sting1 ablation or pharmacological STING inhibition [PMID:40644312, PMID:30135079]. Beyond ERAD, NGLY1 has enzyme-independent scaffolding roles in cell polarity and neuronal branching in invertebrate orthologs [PMID:19940117, PMID:20130186].","teleology":[{"year":2000,"claim":"Established the core biochemical identity: NGLY1's yeast ortholog is a soluble cytosolic/nuclear enzyme with intrinsic PNGase activity whose loss impairs degradation of a misfolded glycoprotein, defining a deglycosylation-to-degradation function.","evidence":"Genetic PNGase-deficiency screen, recombinant E. coli expression with enzymatic assay, and subcellular fractionation in yeast","pmids":["10831608"],"confidence":"High","gaps":["Did not identify the proteasome-coupling partner","Mammalian substrate repertoire undefined"]},{"year":2001,"claim":"Answered how deglycosylation is physically linked to degradation by identifying a Png1p-Rad23p complex distinct from the DNA-repair Rad4p-Rad23p complex, casting Rad23 as the escort to the 26S proteasome.","evidence":"Yeast two-hybrid screen with reciprocal co-immunoprecipitation","pmids":["11259433"],"confidence":"High","gaps":["Did not show requirement of the complex for substrate turnover","Cofactor determinants of substrate specificity unknown"]},{"year":2006,"claim":"Demonstrated functional necessity of the complex: Png1-Rad23 is required for efficient degradation of a glycosylated ERAD substrate, establishing the complex as the operative unit coupling deglycosylation to proteolysis.","evidence":"Genetic deletion of PNG1/RAD23 with glycoprotein (ricin A chain) turnover assays in yeast","pmids":["16401726"],"confidence":"High","gaps":["Limited to a model substrate","No mammalian validation at this stage"]},{"year":2009,"claim":"Revealed that NGLY1 has functions independent of its catalytic activity, since a catalytically dead ortholog is still essential for cell polarity, decoupling scaffolding roles from deglycosylation.","evidence":"Gene deletion and catalytic-mutant morphological analysis in Neurospora crassa","pmids":["19940117"],"confidence":"Medium","gaps":["Single organism, single lab","Molecular basis of the non-catalytic role unresolved","Relevance to mammalian NGLY1 untested"]},{"year":2010,"claim":"Placed NGLY1 in neuronal morphogenesis, showing png-1 acts with rad-23 in the same pathway to restrict axon branching, linking the deglycosylation/degradation axis to nervous-system development.","evidence":"C. elegans loss-of-function screen, tissue-specific rescue, and genetic epistasis with rad-23","pmids":["20130186"],"confidence":"High","gaps":["Substrate driving branching unknown","Catalytic vs scaffolding dependence not dissected"]},{"year":2014,"claim":"Showed that cytosolic versus ER-membrane-associated pools of Png1 have distinct, even opposing, functional consequences on the same substrate class, refining where and how deglycosylation acts.","evidence":"Yeast PNG1 deletion with ricin A chain trafficking, depurination, and toxicity assays","pmids":["25436896"],"confidence":"Medium","gaps":["Substrate-specific generalization unclear","Mechanism of pool partitioning undefined"]},{"year":2015,"claim":"Identified the pathological mechanism of NGLY1 loss: in its absence ENGase generates aggregation-prone N-GlcNAc proteins, and removing ENGase restores ERAD, defining a druggable disease driver.","evidence":"Ngly1-/- and Ngly1-/-/ENGase-/- MEFs with degradation and aggregation assays","pmids":["25605922"],"confidence":"High","gaps":["Organismal relevance not yet established at this stage","Identity of key aggregating substrates undefined"]},{"year":2017,"claim":"Defined a major physiological output by showing NGLY1 deglycosylation of retrotranslocated NRF1 is required for its nuclear translocation and the proteasome bounce-back response, linking NGLY1 to proteostatic transcriptional control.","evidence":"Genetic KO, siRNA, a small-molecule NGLY1 inhibitor, and NRF1 localization/transcription reporter assays in human cells","pmids":["29202016"],"confidence":"High","gaps":["Full NRF1 target program not delineated","Tissue-level consequences untested at this stage"]},{"year":2017,"claim":"Confirmed the ENGase epistasis at the organismal level: ENGase deletion partially rescues Ngly1-/- mouse lethality, validating ENGase-generated N-GlcNAc aggregates as primary disease drivers in vivo.","evidence":"Ngly1-/- x ENGase-/- double-knockout mouse survival analysis","pmids":["28426790"],"confidence":"High","gaps":["Rescue only partial, implying additional pathology","Neurological phenotypes not fully resolved"]},{"year":2018,"claim":"Extended NGLY1 function to organelle quality control and innate immunity, showing NGLY1-NRF1 maintains mitophagy and that its loss chronically activates cGAS-STING/MDA5-MAVS, raising an interferon signature rescuable by NRF2 activation.","evidence":"Human and mouse NGLY1-deficient cells with mitophagy, mitochondrial, and nucleic-acid-sensing pathway assays plus NRF2-activator rescue","pmids":["30135079"],"confidence":"High","gaps":["In vivo contribution of STING not yet tested at this stage","Trigger linking mitochondrial fragmentation to sensing undefined"]},{"year":2018,"claim":"Linked NGLY1 loss to neuroendocrine signaling and confirmed an NRF1 dysfunction signature without ER stress in flies, with ecdysone rescue of developmental delay.","evidence":"Drosophila Pngl loss-of-function model with RNAseq, tissue-specific rescue, and 20-hydroxyecdysone supplementation","pmids":["29346549","29735526"],"confidence":"Medium","gaps":["Mechanism connecting NGLY1 to ecdysteroid production unclear","Mammalian relevance of neuroendocrine axis untested"]},{"year":2019,"claim":"Established tissue-level in vivo requirement for NGLY1 in NRF1 processing, with hepatocyte-specific loss causing impaired NRF1 nuclear localization and lipid/nuclear-morphology defects under dietary stress.","evidence":"Liver-specific conditional Ngly1 knockout mice with NRF1 processing and liver phenotype analysis","pmids":["31733337"],"confidence":"Medium","gaps":["Single tissue, single lab","Contribution relative to ENGase aggregates unquantified"]},{"year":2020,"claim":"Defined an NRF1-independent NGLY1 pathway: NGLY1 loss reduces AMPKα and disrupts energy metabolism across fly, mouse, and patient cells, with epistasis excluding NFE2L1 as the cause.","evidence":"Drosophila tissue-specific genetics, Ngly1-/- MEFs, patient fibroblasts, AMPKα western blot, pharmacological AMPK activation, and NFE2L1 epistasis","pmids":["33315951"],"confidence":"High","gaps":["Molecular basis of AMPKα reduction undefined","Whether AMPKα is a direct substrate unknown"]},{"year":2020,"claim":"Identified candidate functional substrate/modifier NKCC1, whose molecular weight and function are altered in NGLY1-deficient cells, expanding the substrate landscape beyond NRF1.","evidence":"Drosophila genetic diversity panel association plus NGLY1-/- mouse cell NKCC1 functional assays","pmids":["33315011"],"confidence":"Medium","gaps":["Direct deglycosylation of NKCC1 not demonstrated","Mechanism of functional dependence unresolved"]},{"year":2022,"claim":"Connected NGLY1 to ferroptosis resistance, showing NGLY1-dependent NFE2L1 processing maintains GPX4 expression independently of NRF2, defining a distinct cell-survival axis.","evidence":"NGLY1/NFE2L1 KO cell lines with ferroptosis assays, GPX4 analysis, and NFE2L1/NFE2L2 epistasis","pmids":["35271393"],"confidence":"Medium","gaps":["In vivo relevance untested","Single lab"]},{"year":2022,"claim":"Defined the chemistry of NRF1/SKN-1A activation as 'sequence editing' — Asn-to-Asp conversion strictly required for transcriptional activation — clarifying that NGLY1 alters substrate chemistry rather than merely stripping glycans.","evidence":"C. elegans genetics with transcriptomics and selective SKN-1A/SKN-1C mutant alleles (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Generalization of sequence-editing requirement beyond SKN-1A undefined"]},{"year":2022,"claim":"Showed autophagy is a cytoprotective adaptation to NGLY1 loss, with autophagosome induction independent of ER stress, ROS, or Ca2+, and ATG13-dependence for survival.","evidence":"Pharmacological and siRNA NGLY1 inhibition with GFP-LC3 assays, autophagosome IP-MS, and ATG13-KO MEFs","pmids":["34995415"],"confidence":"Medium","gaps":["Trigger of autophagy induction undefined","Pharmacological inhibitor specificity caveats"]},{"year":2023,"claim":"Established cell-type-specific neuronal vulnerability, with NGLY1-deficient human cortical neurons (not astrocytes) showing protein aggregation, mitochondrial, and synaptic defects rescued by NGLY1 reintroduction.","evidence":"Patient iPSC-derived cortical neurons with transcriptomics, proteomics, aggregate LCM-MS, and NGLY1 rescue","pmids":["38039131"],"confidence":"High","gaps":["Causal substrate of aggregation unidentified","Why neurons are selectively vulnerable unresolved"]},{"year":2023,"claim":"Dissected organ-level NGLY1 loss in the gut, showing intestinal barrier defects and JNK/Foxo overactivation drive lethality through non-microbiotal immune/metabolic mechanisms.","evidence":"Tissue-specific Drosophila Pngl knockouts with germ-free rearing, dietary rescue, and JNK/Foxo pathway analysis","pmids":["37704604"],"confidence":"High","gaps":["Mammalian relevance of gut phenotype untested","Direct NGLY1 substrates in this axis unknown"]},{"year":2024,"claim":"Identified an NRF1-independent metabolic modifier axis, showing nucleotide-metabolism gene mutations and nucleotide restriction suppress proteasome dysfunction in NGLY1-deficient worms.","evidence":"C. elegans suppressor screen, epistasis, and dietary nucleotide manipulation","pmids":["38991033"],"confidence":"Medium","gaps":["Mechanism linking nucleotide availability to proteasome function unclear","Single organism"]},{"year":2024,"claim":"Provided practical and mechanistic confirmation of sequence editing, developing an ELISA neo-epitope assay detecting endogenous Asn-to-Asp conversion in patient iPSCs and demonstrating dynamic age-dependent NGLY1 activity in brain.","evidence":"ELISA neo-epitope activity assay in iPSC extracts and FRET-based probe assay in aging rat brain","pmids":["38581946","38417795"],"confidence":"Medium","gaps":["Physiological drivers of age-dependent activity changes unknown","Substrate scope of endogenous editing unquantified"]},{"year":2024,"claim":"Expanded NGLY1's regulatory targets to immune checkpoint control, showing NGLY1 deglycosylates and destabilizes cancer-cell-intrinsic PD-1 upon doxorubicin to sensitize tumor cells.","evidence":"Co-IP, protein half-life assay, NGLY1 siRNA, and viability assays under doxorubicin","pmids":["38782868"],"confidence":"Medium","gaps":["Single Co-IP context","In vivo tumor relevance untested"]},{"year":2024,"claim":"Provided structural context for the downstream fate of NGLY1-processed glycoproteins, resolving how the SCF-FBS2 ligase recognizes residual N-glycan remnants.","evidence":"X-ray crystallography of FBS2-SKP1-Man3GlcNAc2 with NMR and docking","pmids":["39171510"],"confidence":"High","gaps":["Direct functional coupling to NGLY1 not demonstrated biochemically","Druggability not validated cellularly"]},{"year":2025,"claim":"Established the in vivo driver of NGLY1-deficiency neurodegeneration, showing STING ablation or inhibition rescues Purkinje cell loss and motor disease without inflammatory activation and via STING-dependent suppression of glial cholesterol biosynthesis.","evidence":"Postnatal inducible Ngly1 KO mice, Sting1 double-KO rescue, snRNA-seq, and pharmacological STING inhibition (VS-X4)","pmids":["40644312"],"confidence":"High","gaps":["Upstream trigger activating STING in neurons undefined","Link between cholesterol suppression and degeneration mechanistic detail incomplete"]},{"year":2025,"claim":"Implicated NGLY1 in general ERAD capacity beyond specific-substrate deglycosylation, with SEL1L cytoplasmic-tail variants enhancing ERAD in an NGLY1-dependent manner and modifying lethality.","evidence":"CRISPR-engineered Drosophila SEL1L variants with ERAD, ER-stress, and proteasome-inhibition assays","pmids":["40773511"],"confidence":"Medium","gaps":["Direct biochemical NGLY1-SEL1L interaction not shown","Mammalian validation absent"]},{"year":null,"claim":"How NGLY1's distinct catalytic modes (endo- vs exo-glycanase, sequence editing) and its enzyme-independent scaffolding functions are coordinated across substrates and tissues, and which substrates drive neuron-specific pathology, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["Exo-glycanase active site not validated by mutagenesis or structure","Comprehensive endogenous substrate catalog missing","Determinants of cell-type-specific vulnerability unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,6,15,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,19,20]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,2,6]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,13,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,21]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[8,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,7,23]}],"complexes":["Png1-Rad23 complex"],"partners":["RAD23","NFE2L1","PDCD1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96IV0","full_name":"Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase","aliases":["N-glycanase 1","Peptide:N-glycanase"],"length_aa":654,"mass_kda":74.4,"function":"Specifically deglycosylates the denatured form of N-linked glycoproteins in the cytoplasm and assists their proteasome-mediated degradation. Cleaves the beta-aspartyl-glucosamine (GlcNAc) of the glycan and the amide side chain of Asn, converting Asn to Asp. Prefers proteins containing high-mannose over those bearing complex type oligosaccharides. Can recognize misfolded proteins in the endoplasmic reticulum that are exported to the cytosol to be destroyed and deglycosylate them, while it has no activity toward native proteins. Deglycosylation is a prerequisite for subsequent proteasome-mediated degradation of some, but not all, misfolded glycoproteins","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q96IV0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NGLY1","classification":"Not Classified","n_dependent_lines":164,"n_total_lines":1208,"dependency_fraction":0.1357615894039735},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"VCP","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NGLY1","total_profiled":1310},"omim":[{"mim_id":"615273","title":"CONGENITAL DISORDER OF DEGLYCOSYLATION 1; CDDG1","url":"https://www.omim.org/entry/615273"},{"mim_id":"613420","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1","url":"https://www.omim.org/entry/613420"},{"mim_id":"610661","title":"N-GLYCANASE 1; NGLY1","url":"https://www.omim.org/entry/610661"},{"mim_id":"212065","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A","url":"https://www.omim.org/entry/212065"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NGLY1"},"hgnc":{"alias_symbol":["FLJ11005","PNG1","PNG-1"],"prev_symbol":[]},"alphafold":{"accession":"Q96IV0","domains":[{"cath_id":"1.20.58.2190","chopping":"16-113","consensus_level":"high","plddt":92.6381,"start":16,"end":113},{"cath_id":"3.10.620.30","chopping":"171-452","consensus_level":"medium","plddt":92.5944,"start":171,"end":452},{"cath_id":"2.60.120.1020","chopping":"481-654","consensus_level":"high","plddt":93.333,"start":481,"end":654}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96IV0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96IV0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96IV0-F1-predicted_aligned_error_v6.png","plddt_mean":85.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NGLY1","jax_strain_url":"https://www.jax.org/strain/search?query=NGLY1"},"sequence":{"accession":"Q96IV0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96IV0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96IV0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96IV0"}},"corpus_meta":[{"pmid":"24651605","id":"PMC_24651605","title":"Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway.","date":"2014","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24651605","citation_count":181,"is_preprint":false},{"pmid":"10831608","id":"PMC_10831608","title":"PNG1, a yeast gene encoding a highly conserved peptide:N-glycanase.","date":"2000","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10831608","citation_count":179,"is_preprint":false},{"pmid":"29202016","id":"PMC_29202016","title":"Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.","date":"2017","source":"ACS central science","url":"https://pubmed.ncbi.nlm.nih.gov/29202016","citation_count":156,"is_preprint":false},{"pmid":"27388694","id":"PMC_27388694","title":"Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation.","date":"2016","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27388694","citation_count":124,"is_preprint":false},{"pmid":"16401726","id":"PMC_16401726","title":"The Png1-Rad23 complex regulates glycoprotein turnover.","date":"2006","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16401726","citation_count":108,"is_preprint":false},{"pmid":"30135079","id":"PMC_30135079","title":"N-glycanase NGLY1 regulates mitochondrial homeostasis and inflammation through NRF1.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30135079","citation_count":106,"is_preprint":false},{"pmid":"11259433","id":"PMC_11259433","title":"Rad23 provides a link between the Png1 deglycosylating enzyme and the 26 S proteasome in yeast.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11259433","citation_count":105,"is_preprint":false},{"pmid":"25605922","id":"PMC_25605922","title":"Endo-β-N-acetylglucosaminidase forms N-GlcNAc protein aggregates during ER-associated degradation in Ngly1-defective cells.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25605922","citation_count":105,"is_preprint":false},{"pmid":"26611529","id":"PMC_26611529","title":"The cytoplasmic peptide:N-glycanase (NGLY1) - Structure, expression and cellular functions.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26611529","citation_count":104,"is_preprint":false},{"pmid":"35271393","id":"PMC_35271393","title":"Ferroptosis regulation by the NGLY1/NFE2L1 pathway.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35271393","citation_count":85,"is_preprint":false},{"pmid":"28426790","id":"PMC_28426790","title":"Lethality of mice bearing a knockout of the Ngly1-gene is partially rescued by the additional deletion of the Engase gene.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28426790","citation_count":81,"is_preprint":false},{"pmid":"25220016","id":"PMC_25220016","title":"NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathy.","date":"2014","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25220016","citation_count":72,"is_preprint":false},{"pmid":"25398991","id":"PMC_25398991","title":"The cytoplasmic peptide:N-glycanase (Ngly1)-basic science encounters a human genetic disorder.","date":"2014","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25398991","citation_count":55,"is_preprint":false},{"pmid":"32259258","id":"PMC_32259258","title":"Ngly1 -/- rats develop neurodegenerative phenotypes and pathological abnormalities in their peripheral and central nervous systems.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32259258","citation_count":53,"is_preprint":false},{"pmid":"25707956","id":"PMC_25707956","title":"Multi-systemic involvement in NGLY1-related disorder caused by two novel mutations.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25707956","citation_count":51,"is_preprint":false},{"pmid":"28750948","id":"PMC_28750948","title":"Mitochondrial function requires NGLY1.","date":"2017","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/28750948","citation_count":49,"is_preprint":false},{"pmid":"29346549","id":"PMC_29346549","title":"Transcriptome and functional analysis in a Drosophila model of NGLY1 deficiency provides insight into therapeutic approaches.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29346549","citation_count":47,"is_preprint":false},{"pmid":"19940117","id":"PMC_19940117","title":"The Neurospora peptide:N-glycanase ortholog PNG1 is essential for cell polarity despite its lack of enzymatic activity.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19940117","citation_count":42,"is_preprint":false},{"pmid":"9130664","id":"PMC_9130664","title":"Png-1, a nervous system-specific zinc finger gene, identifies regions containing postmitotic neurons during mammalian embryonic development.","date":"1997","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9130664","citation_count":42,"is_preprint":false},{"pmid":"12711318","id":"PMC_12711318","title":"Ngly1, a mouse gene encoding a deglycosylating enzyme implicated in proteasomal degradation: expression, genomic organization, and chromosomal mapping.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12711318","citation_count":40,"is_preprint":false},{"pmid":"31311714","id":"PMC_31311714","title":"Aspartylglycosamine is a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation.","date":"2019","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31311714","citation_count":39,"is_preprint":false},{"pmid":"20130186","id":"PMC_20130186","title":"The N-glycanase png-1 acts to limit axon branching during organ formation in Caenorhabditis elegans.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20130186","citation_count":38,"is_preprint":false},{"pmid":"28512024","id":"PMC_28512024","title":"Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.","date":"2017","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/28512024","citation_count":32,"is_preprint":false},{"pmid":"33315951","id":"PMC_33315951","title":"A conserved role for AMP-activated protein kinase in NGLY1 deficiency.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33315951","citation_count":31,"is_preprint":false},{"pmid":"33315011","id":"PMC_33315011","title":"A Drosophila screen identifies NKCC1 as a modifier of NGLY1 deficiency.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33315011","citation_count":31,"is_preprint":false},{"pmid":"31957011","id":"PMC_31957011","title":"Variants in NGLY1 lead to intellectual disability, myoclonus epilepsy, sensorimotor axonal polyneuropathy and mitochondrial dysfunction.","date":"2020","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31957011","citation_count":31,"is_preprint":false},{"pmid":"35406718","id":"PMC_35406718","title":"NGLY1 Deficiency, a Congenital Disorder of Deglycosylation: From Disease Gene Function to Pathophysiology.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35406718","citation_count":30,"is_preprint":false},{"pmid":"30740912","id":"PMC_30740912","title":"Unexplained death in patients with NGLY1 mutations may be explained by adrenal insufficiency.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/30740912","citation_count":29,"is_preprint":false},{"pmid":"32395402","id":"PMC_32395402","title":"NGLY1 deficiency-A rare congenital disorder of deglycosylation.","date":"2020","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/32395402","citation_count":27,"is_preprint":false},{"pmid":"31733337","id":"PMC_31733337","title":"Liver-specific deletion of Ngly1 causes abnormal nuclear morphology and lipid metabolism under food stress.","date":"2019","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31733337","citation_count":25,"is_preprint":false},{"pmid":"31965062","id":"PMC_31965062","title":"Novel NGLY1 gene variants in Chinese children with global developmental delay, microcephaly, hypotonia, hypertransaminasemia, alacrimia, and feeding difficulty.","date":"2020","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31965062","citation_count":25,"is_preprint":false},{"pmid":"34120625","id":"PMC_34120625","title":"Reversibility of motor dysfunction in the rat model of NGLY1 deficiency.","date":"2021","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/34120625","citation_count":25,"is_preprint":false},{"pmid":"33497766","id":"PMC_33497766","title":"NGLY1 deficiency: Novel variants and literature review.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33497766","citation_count":24,"is_preprint":false},{"pmid":"33563880","id":"PMC_33563880","title":"JF1/B6F1 Ngly1-/- mouse as an isogenic animal model of NGLY1 deficiency.","date":"2021","source":"Proceedings of the Japan Academy. Series B, Physical and biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33563880","citation_count":24,"is_preprint":false},{"pmid":"31615832","id":"PMC_31615832","title":"Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31615832","citation_count":24,"is_preprint":false},{"pmid":"29735526","id":"PMC_29735526","title":"Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency.","date":"2018","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/29735526","citation_count":24,"is_preprint":false},{"pmid":"36102038","id":"PMC_36102038","title":"N-glycoproteomics reveals distinct glycosylation alterations in NGLY1-deficient patient-derived dermal fibroblasts.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/36102038","citation_count":22,"is_preprint":false},{"pmid":"34697629","id":"PMC_34697629","title":"GlcNAc-Asn is a biomarker for NGLY1 deficiency.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34697629","citation_count":22,"is_preprint":false},{"pmid":"36320418","id":"PMC_36320418","title":"AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 Deficiency.","date":"2022","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/36320418","citation_count":20,"is_preprint":false},{"pmid":"31497478","id":"PMC_31497478","title":"Transiently elevated plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine: Unreported laboratory findings in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation.","date":"2019","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/31497478","citation_count":20,"is_preprint":false},{"pmid":"32422350","id":"PMC_32422350","title":"Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.","date":"2020","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32422350","citation_count":19,"is_preprint":false},{"pmid":"30385822","id":"PMC_30385822","title":"Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1.","date":"2018","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30385822","citation_count":18,"is_preprint":false},{"pmid":"37704604","id":"PMC_37704604","title":"Gut barrier defects, intestinal immune hyperactivation and enhanced lipid catabolism drive lethality in NGLY1-deficient Drosophila.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37704604","citation_count":18,"is_preprint":false},{"pmid":"33673403","id":"PMC_33673403","title":"NGLY1 Deficiency: A Rare Newly Described Condition with a Typical Presentation.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33673403","citation_count":18,"is_preprint":false},{"pmid":"35653343","id":"PMC_35653343","title":"An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35653343","citation_count":17,"is_preprint":false},{"pmid":"32071843","id":"PMC_32071843","title":"NGLY1 deficiency: Novel patient, review of the literature and diagnostic algorithm.","date":"2020","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/32071843","citation_count":17,"is_preprint":false},{"pmid":"38039131","id":"PMC_38039131","title":"NGLY1 mutations cause protein aggregation in human neurons.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38039131","citation_count":16,"is_preprint":false},{"pmid":"36875753","id":"PMC_36875753","title":"Generation and characterization of NGLY1 patient-derived midbrain organoids.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36875753","citation_count":16,"is_preprint":false},{"pmid":"35243670","id":"PMC_35243670","title":"Delineating the epilepsy phenotype of NGLY1 deficiency.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/35243670","citation_count":16,"is_preprint":false},{"pmid":"34995415","id":"PMC_34995415","title":"Off-target inhibition of NGLY1 by the polycaspase inhibitor Z-VAD-fmk induces cellular autophagy.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/34995415","citation_count":15,"is_preprint":false},{"pmid":"37951368","id":"PMC_37951368","title":"NGLY1: A fascinating, multifunctional molecule.","date":"2023","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/37951368","citation_count":14,"is_preprint":false},{"pmid":"37379343","id":"PMC_37379343","title":"NGLY1 deficiency: a prospective natural history study.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37379343","citation_count":14,"is_preprint":false},{"pmid":"34580715","id":"PMC_34580715","title":"Physiological importance of NGLY1, as revealed by rodent model analyses.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34580715","citation_count":12,"is_preprint":false},{"pmid":"34791337","id":"PMC_34791337","title":"Assay for the peptide:N-glycanase/NGLY1 and disease-specific biomarkers for diagnosing NGLY1 deficiency.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34791337","citation_count":10,"is_preprint":false},{"pmid":"35769264","id":"PMC_35769264","title":"NGLY1 Deficiency Zebrafish Model Manifests Abnormalities of the Nervous and Musculoskeletal Systems.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35769264","citation_count":10,"is_preprint":false},{"pmid":"34969094","id":"PMC_34969094","title":"Ever-expanding NGLY1 biology.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34969094","citation_count":9,"is_preprint":false},{"pmid":"34697631","id":"PMC_34697631","title":"NGLY1: insights from Caenorhabditis elegans.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34697631","citation_count":9,"is_preprint":false},{"pmid":"38417795","id":"PMC_38417795","title":"Development of a fluorescence and quencher-based FRET assay for detection of endogenous peptide:N-glycanase/NGLY1 activity.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38417795","citation_count":9,"is_preprint":false},{"pmid":"40644312","id":"PMC_40644312","title":"The STING pathway drives noninflammatory neurodegeneration in NGLY1 deficiency.","date":"2025","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40644312","citation_count":7,"is_preprint":false},{"pmid":"20502699","id":"PMC_20502699","title":"Characterization of the temperature-sensitive mutations un-7 and png-1 in Neurospora crassa.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20502699","citation_count":7,"is_preprint":false},{"pmid":"35294432","id":"PMC_35294432","title":"Cytosolic O-GlcNAcylation and PNG1 maintain Drosophila gut homeostasis by regulating proliferation and apoptosis.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35294432","citation_count":6,"is_preprint":false},{"pmid":"30612078","id":"PMC_30612078","title":"Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30612078","citation_count":6,"is_preprint":false},{"pmid":"38991033","id":"PMC_38991033","title":"Mutations in nucleotide metabolism genes bypass proteasome defects in png-1/NGLY1-deficient Caenorhabditis elegans.","date":"2024","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/38991033","citation_count":5,"is_preprint":false},{"pmid":"39206713","id":"PMC_39206713","title":"Development of new NGLY1 assay systems - toward developing an early screening method for NGLY1 deficiency.","date":"2024","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/39206713","citation_count":5,"is_preprint":false},{"pmid":"38581946","id":"PMC_38581946","title":"ELISA-based highly sensitive assay system for the detection of endogenous NGLY1 activity.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38581946","citation_count":5,"is_preprint":false},{"pmid":"38697387","id":"PMC_38697387","title":"Ocular features of NGLY1 deficiency from a prospective longitudinal cohort.","date":"2024","source":"Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus","url":"https://pubmed.ncbi.nlm.nih.gov/38697387","citation_count":5,"is_preprint":false},{"pmid":"26228302","id":"PMC_26228302","title":"New perspectives on the mutated NGLY1 enigma.","date":"2015","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/26228302","citation_count":5,"is_preprint":false},{"pmid":"39137042","id":"PMC_39137042","title":"Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39137042","citation_count":5,"is_preprint":false},{"pmid":"25436896","id":"PMC_25436896","title":"Wild type RTA and less toxic variants have distinct requirements for Png1 for their depurination activity and toxicity in Saccharomyces cerevisiae.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436896","citation_count":5,"is_preprint":false},{"pmid":"38782868","id":"PMC_38782868","title":"Doxorubicin induces deglycosylation of cancer cell-intrinsic PD-1 by NGLY1.","date":"2024","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/38782868","citation_count":4,"is_preprint":false},{"pmid":"38649481","id":"PMC_38649481","title":"Intranasal oxytocin suppresses seizure-like behaviors in a mouse model of NGLY1 deficiency.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38649481","citation_count":4,"is_preprint":false},{"pmid":"31326749","id":"PMC_31326749","title":"An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene.","date":"2019","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31326749","citation_count":4,"is_preprint":false},{"pmid":"36209585","id":"PMC_36209585","title":"Comparative proteomics reveals elevated CCN2 in NGLY1-deficient cells.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36209585","citation_count":3,"is_preprint":false},{"pmid":"39171510","id":"PMC_39171510","title":"Structural basis of sugar recognition by SCFFBS2 ubiquitin ligase involved in NGLY1 deficiency.","date":"2024","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/39171510","citation_count":3,"is_preprint":false},{"pmid":"34619643","id":"PMC_34619643","title":"Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34619643","citation_count":3,"is_preprint":false},{"pmid":"36589922","id":"PMC_36589922","title":"An induced pluripotent stem cell-derived NMJ platform for study of the NGLY1-Congenital Disorder of Deglycosylation.","date":"2022","source":"Advanced therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36589922","citation_count":3,"is_preprint":false},{"pmid":"40730667","id":"PMC_40730667","title":"NGLY1 deficiency - clinical features and therapeutic strategy.","date":"2025","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40730667","citation_count":2,"is_preprint":false},{"pmid":"38628705","id":"PMC_38628705","title":"Functional prediction of the potential NGLY1 mutations associated with rare disease CDG.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38628705","citation_count":2,"is_preprint":false},{"pmid":"40189184","id":"PMC_40189184","title":"Increased oxidative stress and autophagy in NGLY1 patient iPSC-derived neural stem cells.","date":"2025","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40189184","citation_count":2,"is_preprint":false},{"pmid":"40773511","id":"PMC_40773511","title":"Natural SEL1L variants rescue a model of NGLY1 deficiency and modify ERAD function and proteasome sensitivity.","date":"2025","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40773511","citation_count":2,"is_preprint":false},{"pmid":"40470739","id":"PMC_40470739","title":"Impaired Proteostasis is Linked to Neurological Pathology in a Zebrafish NGLY1 Deficiency Model.","date":"2025","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/40470739","citation_count":2,"is_preprint":false},{"pmid":"41229635","id":"PMC_41229635","title":"Tofacitinib Improves Motor Symptoms in Parkinsonism Associated with a Heterozygous NGLY1 Variant and Autoimmune Disease.","date":"2025","source":"European journal of case reports in internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41229635","citation_count":2,"is_preprint":false},{"pmid":"41176936","id":"PMC_41176936","title":"AAV9-mediated NGLY1 gene replacement suppresses non-epileptic convulsions in Ngly1-/- rats.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/41176936","citation_count":1,"is_preprint":false},{"pmid":"40811347","id":"PMC_40811347","title":"Comparative proteomics of HepG2 cells reveals NGLY1 as an important regulator of ferroptosis resistance and iron uptake.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40811347","citation_count":1,"is_preprint":false},{"pmid":"38067490","id":"PMC_38067490","title":"A Natural Compound Containing a Disaccharide Structure of Glucose and Rhamnose Identified as Potential N-Glycanase 1 (NGLY1) Inhibitors.","date":"2023","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38067490","citation_count":1,"is_preprint":false},{"pmid":"40687377","id":"PMC_40687377","title":"Preclinical pharmacology and safety studies to support an AAV9 NGLY1 gene therapy clinical trial for the treatment of NGLY1 deficiency.","date":"2025","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/40687377","citation_count":1,"is_preprint":false},{"pmid":"34051448","id":"PMC_34051448","title":"An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34051448","citation_count":1,"is_preprint":false},{"pmid":"39803314","id":"PMC_39803314","title":"An Assay System for Plate-based Detection of Endogenous Peptide:N-glycanase/NGLY1 Activity Using A Fluorescence-based Probe.","date":"2025","source":"Bio-protocol","url":"https://pubmed.ncbi.nlm.nih.gov/39803314","citation_count":1,"is_preprint":false},{"pmid":"40602583","id":"PMC_40602583","title":"Unveiling roles of NGLY1 in cellular homeostasis and related diseases.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40602583","citation_count":0,"is_preprint":false},{"pmid":"41096971","id":"PMC_41096971","title":"NGLY1 as an Emerging Critical Modulator for Neurodevelopment and Pathogenesis in the Brain.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41096971","citation_count":0,"is_preprint":false},{"pmid":"42052850","id":"PMC_42052850","title":"Discovering the Hidden Power of NGLY1: Orchestrating Immune Cell Functions and Autoimmune Diseases.","date":"2026","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/42052850","citation_count":0,"is_preprint":false},{"pmid":"41081738","id":"PMC_41081738","title":"Structural characterization and insights into the formation of N-acetylglucosaminylasparagine and its derivatives in NGLY1-deficient models and patients.","date":"2025","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/41081738","citation_count":0,"is_preprint":false},{"pmid":"41917400","id":"PMC_41917400","title":"Cytosolic Peptide: N-Glycanase (NGLY1)-from Basic Biology to Genetic Disorder, NGLY1 Deficiency.","date":"2026","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/41917400","citation_count":0,"is_preprint":false},{"pmid":"40810208","id":"PMC_40810208","title":"NGLY1-CDDG: report of two cases from India and brief review of literature.","date":"2025","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40810208","citation_count":0,"is_preprint":false},{"pmid":"41721346","id":"PMC_41721346","title":"Progressive neurodegeneration, motor decline, and premature mortality in aging Ngly1 deficient rats.","date":"2026","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/41721346","citation_count":0,"is_preprint":false},{"pmid":"40395312","id":"PMC_40395312","title":"Sugar coating autophagy: exploring the links between the inhibition of NGLY1 (N-glycanase 1) and autophagy induction.","date":"2023","source":"Autophagy reports","url":"https://pubmed.ncbi.nlm.nih.gov/40395312","citation_count":0,"is_preprint":false},{"pmid":"42114141","id":"PMC_42114141","title":"Natural history of NGLY1 deficiency: motor function & clinical features.","date":"2026","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/42114141","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.29.635299","title":"Protein sequence editing defines distinct and overlapping functions of SKN-1A/Nrf1 and SKN-1C/Nrf2","date":"2025-01-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.29.635299","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.21.671495","title":"Identification and characterization of a novel exo-(N-)glycanase activity of NGLY1 on ENGase-digested N-GlcNAc proteins  <i>in vitro</i>","date":"2025-08-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.21.671495","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.06.641902","title":"Natural  <i>SEL1L</i>  variants modify ERAD, proteasome function, and survival in a  <i>Drosophila</i>  model of NGLY1 deficiency","date":"2025-03-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.641902","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47617,"output_tokens":7596,"usd":0.128395,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17078,"output_tokens":7124,"usd":0.131745,"stage2_stop_reason":"end_turn"},"total_usd":0.26014,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"PNG1 (yeast ortholog of NGLY1) encodes a soluble cytosolic/nuclear peptide:N-glycanase; when expressed in E. coli it exhibits PNGase enzymatic activity, cleaving N-glycans from glycoproteins/glycopeptides. Subcellular fractionation showed Png1p is present in both nucleus and cytosol. Loss of png1 function reduces efficiency of proteasome-mediated degradation of a misfolded glycoprotein.\",\n      \"method\": \"Genetic screen for PNGase-deficient mutants, recombinant expression in E. coli with enzymatic activity assay, subcellular fractionation/localization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution in E. coli, genetic loss-of-function with defined degradation phenotype, subcellular fractionation; foundational paper replicated across multiple subsequent studies\",\n      \"pmids\": [\"10831608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Yeast Png1p (NGLY1 ortholog) physically interacts with Rad23p, a ubiquitin-binding protein that links substrates to the 26S proteasome. The Png1p-Rad23p complex is distinct from the Rad4p-Rad23p DNA repair complex. Rad23p is proposed to act as an escort linking Png1p (and thus deglycosylated substrates) to the 26S proteasome.\",\n      \"method\": \"Two-hybrid screening, co-immunoprecipitation (in vivo biochemical confirmation)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — interaction identified by yeast two-hybrid and confirmed by reciprocal biochemical co-IP; replicated and extended in subsequent studies\",\n      \"pmids\": [\"11259433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The Png1-Rad23 complex in yeast is required for efficient degradation of a glycosylated ERAD substrate (glycosylated ricin A chain), coupling protein deglycosylation to proteasomal degradation. Rad23 binds various regulators of proteolysis to facilitate degradation of distinct substrates, with substrate specificity determined by interactions with cofactors.\",\n      \"method\": \"Genetic deletion of PNG1/RAD23, glycoprotein turnover assay (glycosylated ricin A chain degradation), protein interaction studies\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function with defined substrate degradation readout, functional complex characterized, replicated across labs\",\n      \"pmids\": [\"16401726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The Neurospora crassa PNG1 ortholog has substitutions in essential catalytic amino acids, abolishing deglycosylation activity, yet PNG1 is essential for cell polarity; its deletion causes strong polarity defects. This reveals an enzyme-independent (non-catalytic) scaffolding function of PNG1 in polar cell growth, distinct from its role in ERAD.\",\n      \"method\": \"Gene deletion, catalytic mutant analysis, morphological phenotyping in Neurospora crassa\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined polarity phenotype and catalytic mutant showing enzyme-independent function; single organism, single lab\",\n      \"pmids\": [\"19940117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Loss-of-function mutations in C. elegans png-1 (NGLY1 ortholog) cause increased axon branching during morphogenesis of vulval egg-laying neurons (VC4, VC5) and nearby axons. PNG-1 acts from both neurons and epithelial cells to restrict axon branching. Genetic interaction with rad-23 (Rad23 ortholog) shows similar branching defects, placing png-1 and rad-23 in the same pathway regulating neuronal branching during organ innervation.\",\n      \"method\": \"Loss-of-function genetic screen in C. elegans, neuronal morphology analysis, tissue-specific rescue, genetic epistasis with rad-23\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function with defined neuronal phenotype, tissue-specific rescue, genetic epistasis; multiple orthogonal approaches in single rigorous study\",\n      \"pmids\": [\"20130186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In Ngly1-/- mouse embryonic fibroblasts (MEFs), loss of Ngly1 causes delayed degradation of misfolded ERAD substrates. In the absence of Ngly1, ENGase (endo-β-N-acetylglucosaminidase) performs an alternative deglycosylation reaction generating N-GlcNAc proteins that are aggregation-prone. Additional knockout of ENGase in Ngly1-/- cells restores normal ERAD processing, demonstrating that ENGase-generated N-GlcNAc protein aggregates underlie ERAD dysregulation in NGLY1 deficiency.\",\n      \"method\": \"MEF knockout cell lines (Ngly1-/- and Ngly1-/-/ENGase-/-), glycoprotein degradation assays, protein aggregation analysis, genetic epistasis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double knockout genetic epistasis with defined ERAD substrate degradation and aggregation readouts; multiple orthogonal methods in single study\",\n      \"pmids\": [\"25605922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NGLY1 (human cytosolic N-glycanase) is essential for activation of the transcription factor NFE2L1 (Nrf1) in response to proteasome inhibition. NGLY1 processes retrotranslocated, N-glycosylated Nrf1 by removing its N-glycans; chemical or genetic disruption of NGLY1 results in misprocessed Nrf1 that is excluded from the nucleus and cannot upregulate proteasome subunit gene expression (the 'bounce-back' response). A small-molecule NGLY1 inhibitor was identified that disrupts Nrf1 processing and potentiates proteasome inhibitor cytotoxicity.\",\n      \"method\": \"Genetic KO, siRNA knockdown, small-molecule NGLY1 inhibitor, reporter assays for Nrf1 nuclear localization and transcriptional activity, cell viability assays\",\n      \"journal\": \"ACS central science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic KO, RNAi, chemical inhibitor) with defined mechanistic readout (Nrf1 processing, nuclear localization, transcriptional activity); replicated across cell lines\",\n      \"pmids\": [\"29202016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Lethality of Ngly1-/- mice (C57BL/6 background) is partially rescued by additional deletion of the ENGase gene, establishing a genetic epistasis relationship. This demonstrates that ENGase-generated N-GlcNAc protein aggregates are a primary pathological driver in NGLY1 deficiency, and identifies cytoplasmic ENGase as a potential therapeutic target.\",\n      \"method\": \"Double knockout mouse genetics (Ngly1-/- x ENGase-/-), survival analysis, phenotypic rescue\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with survival endpoint; confirms prior MEF cell data at organismal level\",\n      \"pmids\": [\"28426790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NGLY1 regulates mitochondrial homeostasis through the transcription factor NRF1 (NFE2L1). NGLY1-deficient human and mouse cells show impaired mitochondrial clearance by mitophagy, resulting in fragmented mitochondria and chronic activation of cytosolic nucleic acid-sensing pathways (cGAS-STING and MDA5-MAVS), leading to elevated interferon gene signature. Pharmacological activation of NRF2, a non-glycosylated homolog of NRF1, restores mitochondrial homeostasis and suppresses immune gene activation in NGLY1-deficient cells.\",\n      \"method\": \"NGLY1-deficient human and mouse cell lines, mitophagy assays, mitochondrial morphology/function assays, cGAS-STING/MDA5-MAVS pathway activation measurements, NRF2 activator rescue experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (mitophagy assay, pathway activation, pharmacological rescue) across human and mouse cells with mechanistic pathway placement\",\n      \"pmids\": [\"30135079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In a Drosophila model of NGLY1 deficiency (loss of Pngl), transcriptome analysis shows no evidence of ER stress but reveals strong NRF1 dysfunction signature (downregulation of proteasome components and oxidation-reduction genes). Loss of NGLY1 is functionally linked to defects in neuroendocrine signaling; targeted NGLY1 expression in prothoracic gland (ecdysteroid-producing tissue) or supplementation with the molting hormone 20-hydroxyecdysone partially rescues developmental delay.\",\n      \"method\": \"Drosophila Pngl loss-of-function model, RNAseq transcriptome analysis, tissue-specific rescue (Gal4/UAS), pharmacological rescue (20-hydroxyecdysone)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics plus genetic/pharmacological rescue in Drosophila; mechanistic pathway placement through NRF1 signature and neuroendocrine axis\",\n      \"pmids\": [\"29346549\", \"29735526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of NGLY1 in Drosophila visceral muscle leads to severely reduced AMPKα (AMP-activated protein kinase α) levels, causing energy metabolism defects, impaired gut peristalsis, and animal lethality. Reduced AMPKα levels are also observed in Ngly1-/- mouse embryonic fibroblasts and NGLY1-deficient patient fibroblasts. Pharmacological AMPK activation suppresses energy metabolism defects. This AMPKα reduction is not caused by loss of NFE2L1 activity, defining an NRF1-independent NGLY1 pathway.\",\n      \"method\": \"Drosophila tissue-specific genetics, Ngly1-/- MEFs, patient fibroblasts, AMPKα western blot, pharmacological AMPK activation, epistasis with NFE2L1\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conserved finding across three species/models (fly, mouse, human patient cells), multiple orthogonal methods, epistasis establishing NRF1-independence\",\n      \"pmids\": [\"33315951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of NGLY1 in a Drosophila genetic diversity panel reveals NKCC1/2 (ion cotransporter; Drosophila Ncc69) as a modifier of NGLY1 deficiency lethality. In NGLY1-/- mouse cells, NKCC1 shows altered average molecular weight and reduced function, suggesting NKCC1 is a relevant NGLY1 substrate or functionally dependent on NGLY1 activity.\",\n      \"method\": \"Drosophila NGLY1 deficiency model crossed to genetically diverse strains, association analysis, evolutionary rate covariation, NGLY1-/- mouse cell NKCC1 functional assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic screen plus functional validation in mouse cells across two model systems; NKCC1 mechanism not fully resolved at molecular level\",\n      \"pmids\": [\"33315011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Yeast Png1p deglycosylates ricin A chain (RTA) in the cytosol, and this deglycosylation increases RTA depurination activity by apparently protecting it from ERAD-mediated degradation. In contrast, for a less toxic G83D variant, Png1p deglycosylation on the ER membrane promotes its degradation and reduces toxicity, demonstrating that the free cytosolic pool vs. ER-membrane-associated Png1 have distinct substrate preferences and opposing functional consequences.\",\n      \"method\": \"Yeast genetic deletion of PNG1, EGFP-tagged RTA trafficking assays, depurination activity assays, toxicity assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic loss-of-function with defined enzymatic and toxicity readouts; single lab, multiple substrates tested\",\n      \"pmids\": [\"25436896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of Ngly1 in hepatocyte-specific conditional knockout mice causes impaired processing and nuclear localization of Nfe2l1 (NRF1) in hepatocytes, contributing to abnormal hepatocyte nuclear morphology and lipid accumulation under high-fructose diet stress. This establishes that NGLY1 is required for proper Nfe2l1 processing and function in liver tissue in vivo.\",\n      \"method\": \"Liver-specific Cre-loxP conditional Ngly1 knockout mice, Nfe2l1 processing/localization assays, liver phenotype analysis under dietary stress\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific in vivo KO with defined molecular (Nfe2l1 processing) and phenotypic (nuclear morphology, lipid) readouts; single lab\",\n      \"pmids\": [\"31733337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFE2L1/NRF1 promotes ferroptosis resistance through maintaining expression of glutathione peroxidase 4 (GPX4), and this function requires NGLY1-dependent processing of NFE2L1. NGLY1-mediated NFE2L1 activation is independent of NFE2L2/NRF2, establishing that the NGLY1-NFE2L1 axis constitutes a distinct pathway regulating ferroptosis.\",\n      \"method\": \"NGLY1/NFE2L1 genetic KO cell lines, ferroptosis assays, GPX4 expression analysis, epistasis between NFE2L1 and NFE2L2\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined ferroptosis/GPX4 readout and epistasis; single lab, multiple cell lines\",\n      \"pmids\": [\"35271393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In C. elegans, PNG-1/NGLY1 deglycosylates the transcription factor SKN-1A/Nrf1 by converting N-glycosylated asparagine residues to aspartate ('sequence editing'), and this chemical conversion is strictly required for SKN-1A transcriptional activation of proteasome subunit genes. Sequence-edited SKN-1A can also activate redox homeostasis and xenobiotic detoxification genes normally regulated by SKN-1C/Nrf2, but sequence editing itself antagonizes the extent of this activation.\",\n      \"method\": \"C. elegans genetics, transcriptomic analysis, mutant alleles selectively inactivating SKN-1A or SKN-1C, deglycosylation/sequence editing assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic approach with transcriptomic readout, multiple selective mutant alleles; preprint, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NGLY1 inhibition (pharmacological via Z-VAD-fmk, or siRNA knockdown) induces upregulation of autophagosome formation without impairing autophagic flux in HEK293 cells. This autophagy induction does not involve ER stress markers, ROS, or altered Ca2+ handling. ATG13-deficient MEFs show reduced viability under NGLY1 inhibition, establishing that autophagy is a cytoprotective adaptation to NGLY1 loss.\",\n      \"method\": \"Pharmacological NGLY1 inhibition (Z-VAD-fmk), siRNA knockdown, GFP-LC3 puncta assay, autophagosome immunoprecipitation with mass spectrometry, ATG13-KO MEFs\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods of NGLY1 inhibition with autophagy readout, genetic validation with ATG13 KO; single lab\",\n      \"pmids\": [\"34995415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NGLY1 physically interacts with and deglycosylates cancer cell-intrinsic PD-1 in response to doxorubicin treatment. Doxorubicin promotes the interaction between NGLY1 and PD-1, facilitating NGLY1-mediated PD-1 deglycosylation and destabilization (shortening PD-1 half-life), thereby sensitizing tumor cells to doxorubicin's antiproliferative effects.\",\n      \"method\": \"Co-immunoprecipitation (NGLY1-PD-1 interaction), protein half-life assay, siRNA knockdown of NGLY1, doxorubicin treatment, cell viability assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating interaction, protein stability assay, and functional cell viability readout; single lab, single paper\",\n      \"pmids\": [\"38782868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Crystal structure of bovine FBS2 (component of SCF-FBS2 ubiquitin ligase) complexed with SKP1 and the N-glycan core pentasaccharide Man3GlcNAc2 was determined, revealing the structural basis for sugar recognition. NMR data revealed disparate sugar-binding specificities among homologous FBS proteins and identified a druggable pocket. FBS2 recognizes N-glycan remnants on proteins processed in the NGLY1/ERAD pathway.\",\n      \"method\": \"X-ray crystallography, NMR spectroscopy, in silico docking\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus NMR validation; single lab but two orthogonal structural methods\",\n      \"pmids\": [\"39171510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NGLY1 possesses a 'sequence editing' enzymatic function: it converts N-glycosylated asparagine residues to aspartate residues on substrate proteins (not merely removing glycans), introducing negative charges into the core peptide. An ELISA-based assay using this Asn-to-Asp conversion to generate a neo-epitope confirmed endogenous NGLY1 activity detectable in as few as 5×10³ cells, including patient-derived iPSCs.\",\n      \"method\": \"ELISA-based activity assay exploiting Asn-to-Asp conversion (neo-epitope detection by anti-HA antibody), crude cell extract from patient and control iPSCs\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with defined chemical conversion readout; functional validation in patient-derived cells; single lab\",\n      \"pmids\": [\"38581946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A FRET-based probe assay revealed significant changes in NGLY1 enzymatic activity in rat brains during aging, demonstrating that endogenous NGLY1 activity is dynamically regulated in the central nervous system under physiological conditions.\",\n      \"method\": \"FRET-based fluorescent glycopeptide probe, plate-based assay of endogenous NGLY1 activity in rat brain tissues across ages\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative in vitro enzymatic assay of endogenous enzyme; novel finding about age-dependent regulation; single lab\",\n      \"pmids\": [\"38417795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The STING pathway drives noninflammatory neurodegeneration in NGLY1 deficiency. In postnatal inducible whole-body Ngly1 knockout mice, genetic ablation of Sting1 rescues Purkinje cell loss, improves motor function, and extends lifespan without requiring immune/inflammatory activation. Single-nucleus RNA sequencing reveals STING-dependent suppression of cholesterol biosynthesis in glia. Pharmacological STING inhibition with VS-X4 mitigates neuropathology and motor disease.\",\n      \"method\": \"Postnatal inducible Ngly1 KO mouse, genetic Sting1 ablation (double KO), single-nucleus RNA sequencing, pharmacological STING inhibition (VS-X4), motor function assays, histopathology\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis (double KO rescue), snRNA-seq pathway analysis, pharmacological confirmation with defined neuropathological and behavioral endpoints\",\n      \"pmids\": [\"40644312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of Drosophila N-glycanase 1 (Pngl) in a specific intestinal cell type causes gut barrier defects leading to starvation and JNK overactivation; combined loss in enterocytes and fat body causes Foxo overactivation, hyperactive innate immune response, and enhanced lipid catabolism contributing to lethality. Germ-free rearing rescues developmental delay but not lethality, indicating lethality is primarily driven by non-bacterial immune/metabolic mechanisms rather than microbiota.\",\n      \"method\": \"Tissue-specific Drosophila Pngl knockouts, germ-free rearing, fat-rich diet rescue, JNK/Foxo pathway analysis, intestinal barrier assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific in vivo genetics, multiple epistasis experiments, germ-free and dietary rescue with defined pathway (JNK/Foxo) readouts\",\n      \"pmids\": [\"37704604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NGLY1 deficiency in human iPSC-derived cortical neurons (but not astrocytes) causes protein aggregate accumulation, mitochondrial homeostasis defects, and synaptic dysfunction. Laser capture microscopy and mass spectrometry characterized the composition of protein aggregates specific to NGLY1-deficient neurons. Introduction of functional NGLY1 rescued these phenotypes, confirming direct causality.\",\n      \"method\": \"iPSC direct conversion to cortical neurons, transcriptomics, proteomics, functional assays, NGLY1 rescue, laser capture microscopy and mass spectrometry of aggregates\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — patient iPSC-derived neurons with multiple orthogonal methods (transcriptomics, proteomics, functional assays) and genetic rescue; cell-type specificity established\",\n      \"pmids\": [\"38039131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mutations in nucleotide metabolism genes (rsks-1, tald-1, ent-4) suppress proteasome inhibitor sensitivity caused by PNG-1/NGLY1 inactivation in C. elegans through an SKN-1/Nrf1-independent mechanism. Restriction of nucleotide availability (via ent-4 intestinal nucleoside/nucleotide transporter mutation or dietary manipulation) is beneficial, while a nucleotide-rich diet exacerbates proteasome dysfunction in PNG-1/NGLY1-deficient worms.\",\n      \"method\": \"C. elegans suppressor screen, double mutant epistasis, dietary nucleotide manipulation, proteasome function assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic suppressor screen with epistasis; novel NRF1-independent pathway; single organism/lab\",\n      \"pmids\": [\"38991033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Natural variants in SEL1L (cytoplasmic tail domain, S780P and Δ806-809) modify NGLY1 deficiency lethality in Drosophila by enhancing ERAD function in an NGLY1-dependent manner. This genetic interaction implicates NGLY1 as a contributor to general ERAD function (not solely deglycosylation of specific substrates), and SEL1L variants also protect against proteasome inhibition sensitivity in heterozygous NGLY1 null flies.\",\n      \"method\": \"CRISPR-generated Drosophila SEL1L variant lines, NGLY1 deficiency model genetic interaction, ERAD functional assays, ER stress resistance assays, proteasome inhibition assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR-engineered variants with ERAD functional readouts and genetic interaction with NGLY1; single lab, Drosophila model\",\n      \"pmids\": [\"40773511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NGLY1 exhibits a novel exo-(N-)glycanase activity on ENGase-digested N-GlcNAc proteins in vitro, distinct from its canonical endo-(N-)glycanase activity. Active sites for exo-NGLY1 activity were predicted computationally and differ from those of endo-NGLY1.\",\n      \"method\": \"In vitro enzymatic assay with N-GlcNAc protein substrates, computational active-site prediction/comparison\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — novel in vitro activity described in preprint; single lab, no mutagenesis or structural validation of predicted exo-active site\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"NGLY1 is a cytosolic amidase (peptide:N-glycanase) that removes N-linked glycans from misfolded glycoproteins retrotranslocated from the ER, converting N-glycosylated asparagine residues to aspartate ('sequence editing'); it forms a complex with RAD23 to couple deglycosylation to proteasomal degradation, is essential for NFE2L1/NRF1 transcription factor activation (which requires NGLY1-mediated deglycosylation for nuclear translocation and proteasome bounce-back gene expression), regulates mitochondrial homeostasis and mitophagy through NRF1, controls AMPK signaling and energy metabolism, and activates the STING innate immune pathway under conditions of proteostatic stress; in its absence, the alternative deglycosylase ENGase generates aggregation-prone N-GlcNAc proteins that are the primary pathological drivers of NGLY1 deficiency.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NGLY1 is a soluble cytosolic/nuclear peptide:N-glycanase that drives the cytoplasmic deglycosylation arm of ER-associated degradation (ERAD), removing N-linked glycans from misfolded glycoproteins retrotranslocated from the ER and coupling their turnover to the proteasome [#0, #2]. Rather than simply excising sugars, the enzyme performs 'sequence editing', deamidating the glycosylated asparagine to aspartate and thereby introducing a permanent negative charge into the substrate peptide [#19, #15]. It is escorted to the 26S proteasome through a direct physical interaction with the ubiquitin-binding protein RAD23, which links deglycosylated substrates to degradation [#1, #2]. A central physiological output of this activity is activation of the transcription factor NFE2L1/NRF1: NGLY1-mediated processing of retrotranslocated NRF1 is strictly required for its nuclear entry and induction of the proteasome 'bounce-back' response [#6, #15], and this axis extends to mitochondrial homeostasis and mitophagy, ferroptosis resistance via GPX4, and in vivo hepatic NRF1 function [#8, #14, #13]. NGLY1 also acts through NRF1-independent routes, maintaining AMPKα levels and energy metabolism across fly, mouse, and patient cells [#10]. In NGLY1 deficiency the alternative deglycosidase ENGase generates aggregation-prone N-GlcNAc proteins that are the primary pathological drivers, since deleting ENGase restores ERAD and partially rescues lethality [#5, #7]. Loss of NGLY1 produces neuronal protein aggregation, mitochondrial and synaptic defects in human iPSC-derived cortical neurons [#23], and STING-dependent neurodegeneration in mice that is rescued by Sting1 ablation or pharmacological STING inhibition [#21, #8]. Beyond ERAD, NGLY1 has enzyme-independent scaffolding roles in cell polarity and neuronal branching in invertebrate orthologs [#3, #4].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the core biochemical identity: NGLY1's yeast ortholog is a soluble cytosolic/nuclear enzyme with intrinsic PNGase activity whose loss impairs degradation of a misfolded glycoprotein, defining a deglycosylation-to-degradation function.\",\n      \"evidence\": \"Genetic PNGase-deficiency screen, recombinant E. coli expression with enzymatic assay, and subcellular fractionation in yeast\",\n      \"pmids\": [\"10831608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the proteasome-coupling partner\", \"Mammalian substrate repertoire undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Answered how deglycosylation is physically linked to degradation by identifying a Png1p-Rad23p complex distinct from the DNA-repair Rad4p-Rad23p complex, casting Rad23 as the escort to the 26S proteasome.\",\n      \"evidence\": \"Yeast two-hybrid screen with reciprocal co-immunoprecipitation\",\n      \"pmids\": [\"11259433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not show requirement of the complex for substrate turnover\", \"Cofactor determinants of substrate specificity unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated functional necessity of the complex: Png1-Rad23 is required for efficient degradation of a glycosylated ERAD substrate, establishing the complex as the operative unit coupling deglycosylation to proteolysis.\",\n      \"evidence\": \"Genetic deletion of PNG1/RAD23 with glycoprotein (ricin A chain) turnover assays in yeast\",\n      \"pmids\": [\"16401726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited to a model substrate\", \"No mammalian validation at this stage\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed that NGLY1 has functions independent of its catalytic activity, since a catalytically dead ortholog is still essential for cell polarity, decoupling scaffolding roles from deglycosylation.\",\n      \"evidence\": \"Gene deletion and catalytic-mutant morphological analysis in Neurospora crassa\",\n      \"pmids\": [\"19940117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single organism, single lab\", \"Molecular basis of the non-catalytic role unresolved\", \"Relevance to mammalian NGLY1 untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed NGLY1 in neuronal morphogenesis, showing png-1 acts with rad-23 in the same pathway to restrict axon branching, linking the deglycosylation/degradation axis to nervous-system development.\",\n      \"evidence\": \"C. elegans loss-of-function screen, tissue-specific rescue, and genetic epistasis with rad-23\",\n      \"pmids\": [\"20130186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate driving branching unknown\", \"Catalytic vs scaffolding dependence not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that cytosolic versus ER-membrane-associated pools of Png1 have distinct, even opposing, functional consequences on the same substrate class, refining where and how deglycosylation acts.\",\n      \"evidence\": \"Yeast PNG1 deletion with ricin A chain trafficking, depurination, and toxicity assays\",\n      \"pmids\": [\"25436896\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate-specific generalization unclear\", \"Mechanism of pool partitioning undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the pathological mechanism of NGLY1 loss: in its absence ENGase generates aggregation-prone N-GlcNAc proteins, and removing ENGase restores ERAD, defining a druggable disease driver.\",\n      \"evidence\": \"Ngly1-/- and Ngly1-/-/ENGase-/- MEFs with degradation and aggregation assays\",\n      \"pmids\": [\"25605922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Organismal relevance not yet established at this stage\", \"Identity of key aggregating substrates undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a major physiological output by showing NGLY1 deglycosylation of retrotranslocated NRF1 is required for its nuclear translocation and the proteasome bounce-back response, linking NGLY1 to proteostatic transcriptional control.\",\n      \"evidence\": \"Genetic KO, siRNA, a small-molecule NGLY1 inhibitor, and NRF1 localization/transcription reporter assays in human cells\",\n      \"pmids\": [\"29202016\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full NRF1 target program not delineated\", \"Tissue-level consequences untested at this stage\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Confirmed the ENGase epistasis at the organismal level: ENGase deletion partially rescues Ngly1-/- mouse lethality, validating ENGase-generated N-GlcNAc aggregates as primary disease drivers in vivo.\",\n      \"evidence\": \"Ngly1-/- x ENGase-/- double-knockout mouse survival analysis\",\n      \"pmids\": [\"28426790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rescue only partial, implying additional pathology\", \"Neurological phenotypes not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended NGLY1 function to organelle quality control and innate immunity, showing NGLY1-NRF1 maintains mitophagy and that its loss chronically activates cGAS-STING/MDA5-MAVS, raising an interferon signature rescuable by NRF2 activation.\",\n      \"evidence\": \"Human and mouse NGLY1-deficient cells with mitophagy, mitochondrial, and nucleic-acid-sensing pathway assays plus NRF2-activator rescue\",\n      \"pmids\": [\"30135079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of STING not yet tested at this stage\", \"Trigger linking mitochondrial fragmentation to sensing undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked NGLY1 loss to neuroendocrine signaling and confirmed an NRF1 dysfunction signature without ER stress in flies, with ecdysone rescue of developmental delay.\",\n      \"evidence\": \"Drosophila Pngl loss-of-function model with RNAseq, tissue-specific rescue, and 20-hydroxyecdysone supplementation\",\n      \"pmids\": [\"29346549\", \"29735526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting NGLY1 to ecdysteroid production unclear\", \"Mammalian relevance of neuroendocrine axis untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established tissue-level in vivo requirement for NGLY1 in NRF1 processing, with hepatocyte-specific loss causing impaired NRF1 nuclear localization and lipid/nuclear-morphology defects under dietary stress.\",\n      \"evidence\": \"Liver-specific conditional Ngly1 knockout mice with NRF1 processing and liver phenotype analysis\",\n      \"pmids\": [\"31733337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tissue, single lab\", \"Contribution relative to ENGase aggregates unquantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined an NRF1-independent NGLY1 pathway: NGLY1 loss reduces AMPKα and disrupts energy metabolism across fly, mouse, and patient cells, with epistasis excluding NFE2L1 as the cause.\",\n      \"evidence\": \"Drosophila tissue-specific genetics, Ngly1-/- MEFs, patient fibroblasts, AMPKα western blot, pharmacological AMPK activation, and NFE2L1 epistasis\",\n      \"pmids\": [\"33315951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of AMPKα reduction undefined\", \"Whether AMPKα is a direct substrate unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified candidate functional substrate/modifier NKCC1, whose molecular weight and function are altered in NGLY1-deficient cells, expanding the substrate landscape beyond NRF1.\",\n      \"evidence\": \"Drosophila genetic diversity panel association plus NGLY1-/- mouse cell NKCC1 functional assays\",\n      \"pmids\": [\"33315011\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct deglycosylation of NKCC1 not demonstrated\", \"Mechanism of functional dependence unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected NGLY1 to ferroptosis resistance, showing NGLY1-dependent NFE2L1 processing maintains GPX4 expression independently of NRF2, defining a distinct cell-survival axis.\",\n      \"evidence\": \"NGLY1/NFE2L1 KO cell lines with ferroptosis assays, GPX4 analysis, and NFE2L1/NFE2L2 epistasis\",\n      \"pmids\": [\"35271393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance untested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the chemistry of NRF1/SKN-1A activation as 'sequence editing' — Asn-to-Asp conversion strictly required for transcriptional activation — clarifying that NGLY1 alters substrate chemistry rather than merely stripping glycans.\",\n      \"evidence\": \"C. elegans genetics with transcriptomics and selective SKN-1A/SKN-1C mutant alleles (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Generalization of sequence-editing requirement beyond SKN-1A undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed autophagy is a cytoprotective adaptation to NGLY1 loss, with autophagosome induction independent of ER stress, ROS, or Ca2+, and ATG13-dependence for survival.\",\n      \"evidence\": \"Pharmacological and siRNA NGLY1 inhibition with GFP-LC3 assays, autophagosome IP-MS, and ATG13-KO MEFs\",\n      \"pmids\": [\"34995415\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trigger of autophagy induction undefined\", \"Pharmacological inhibitor specificity caveats\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established cell-type-specific neuronal vulnerability, with NGLY1-deficient human cortical neurons (not astrocytes) showing protein aggregation, mitochondrial, and synaptic defects rescued by NGLY1 reintroduction.\",\n      \"evidence\": \"Patient iPSC-derived cortical neurons with transcriptomics, proteomics, aggregate LCM-MS, and NGLY1 rescue\",\n      \"pmids\": [\"38039131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal substrate of aggregation unidentified\", \"Why neurons are selectively vulnerable unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Dissected organ-level NGLY1 loss in the gut, showing intestinal barrier defects and JNK/Foxo overactivation drive lethality through non-microbiotal immune/metabolic mechanisms.\",\n      \"evidence\": \"Tissue-specific Drosophila Pngl knockouts with germ-free rearing, dietary rescue, and JNK/Foxo pathway analysis\",\n      \"pmids\": [\"37704604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian relevance of gut phenotype untested\", \"Direct NGLY1 substrates in this axis unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified an NRF1-independent metabolic modifier axis, showing nucleotide-metabolism gene mutations and nucleotide restriction suppress proteasome dysfunction in NGLY1-deficient worms.\",\n      \"evidence\": \"C. elegans suppressor screen, epistasis, and dietary nucleotide manipulation\",\n      \"pmids\": [\"38991033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking nucleotide availability to proteasome function unclear\", \"Single organism\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided practical and mechanistic confirmation of sequence editing, developing an ELISA neo-epitope assay detecting endogenous Asn-to-Asp conversion in patient iPSCs and demonstrating dynamic age-dependent NGLY1 activity in brain.\",\n      \"evidence\": \"ELISA neo-epitope activity assay in iPSC extracts and FRET-based probe assay in aging rat brain\",\n      \"pmids\": [\"38581946\", \"38417795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological drivers of age-dependent activity changes unknown\", \"Substrate scope of endogenous editing unquantified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded NGLY1's regulatory targets to immune checkpoint control, showing NGLY1 deglycosylates and destabilizes cancer-cell-intrinsic PD-1 upon doxorubicin to sensitize tumor cells.\",\n      \"evidence\": \"Co-IP, protein half-life assay, NGLY1 siRNA, and viability assays under doxorubicin\",\n      \"pmids\": [\"38782868\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP context\", \"In vivo tumor relevance untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided structural context for the downstream fate of NGLY1-processed glycoproteins, resolving how the SCF-FBS2 ligase recognizes residual N-glycan remnants.\",\n      \"evidence\": \"X-ray crystallography of FBS2-SKP1-Man3GlcNAc2 with NMR and docking\",\n      \"pmids\": [\"39171510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct functional coupling to NGLY1 not demonstrated biochemically\", \"Druggability not validated cellularly\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established the in vivo driver of NGLY1-deficiency neurodegeneration, showing STING ablation or inhibition rescues Purkinje cell loss and motor disease without inflammatory activation and via STING-dependent suppression of glial cholesterol biosynthesis.\",\n      \"evidence\": \"Postnatal inducible Ngly1 KO mice, Sting1 double-KO rescue, snRNA-seq, and pharmacological STING inhibition (VS-X4)\",\n      \"pmids\": [\"40644312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream trigger activating STING in neurons undefined\", \"Link between cholesterol suppression and degeneration mechanistic detail incomplete\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated NGLY1 in general ERAD capacity beyond specific-substrate deglycosylation, with SEL1L cytoplasmic-tail variants enhancing ERAD in an NGLY1-dependent manner and modifying lethality.\",\n      \"evidence\": \"CRISPR-engineered Drosophila SEL1L variants with ERAD, ER-stress, and proteasome-inhibition assays\",\n      \"pmids\": [\"40773511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical NGLY1-SEL1L interaction not shown\", \"Mammalian validation absent\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How NGLY1's distinct catalytic modes (endo- vs exo-glycanase, sequence editing) and its enzyme-independent scaffolding functions are coordinated across substrates and tissues, and which substrates drive neuron-specific pathology, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Exo-glycanase active site not validated by mutagenesis or structure\", \"Comprehensive endogenous substrate catalog missing\", \"Determinants of cell-type-specific vulnerability unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 6, 15, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 19, 20]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 2, 6]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 21]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 7, 23]}\n    ],\n    \"complexes\": [\"Png1-Rad23 complex\"],\n    \"partners\": [\"RAD23\", \"NFE2L1\", \"PDCD1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}